Még nem toboroz
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
NCT07593040· 2. fázis· Vall d'Hebron Institute of Oncology· Forrás
Még nem toboroz
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
2026-526300-67-00· 3. fázis· Summit Therapeutics Inc.· Forrás
Még nem toboroz
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00· 2. fázis· Fundacion PETHEMA· Forrás
Még nem toboroz
A phase II clinical trial of neoadjuvant treatment with Ivonescimab and chemotherapy for stage IIA-IIB-IIIA and IIIB (T3N2) non-small cell lung cancer (NSCLC) patients
2026-525303-27-00· 2. fázis· Fundacion GECP· Forrás
Toboroz
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy.
2025-522771-28-00· 3. fázis· Inmunotek S.L.· Forrás
Toboroz
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· 3. fázis· Janssen Cilag International· Forrás
Még nem toboroz
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
NCT07247786· 2. fázis· Fundación GECP· Forrás
Toboroz
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
NCT07478991· 3. fázis· PETHEMA Foundation· Forrás
Contact: Aitor Abuín, Dr (principal investigator)
Toboroz
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia older than 60 years and/or inelegible for standard induction chemotherapy
2025-523238-17-00· 2. fázis· Fundacion PETHEMA· Forrás
Toboroz
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
NCT07507760· 2. fázis· PETHEMA Foundation· Forrás
Contact: Aitor Abuín, Dr (principal investigator)
Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Még nem toboroz
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
NCT07612657· 3. fázis· VIVUS LLC· Forrás
Toboroz
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547· 2. fázis· Fundación GECP· Forrás
Toboroz
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
2025-522979-29-00· 3. fázis· Fundacion PETHEMA· Forrás
Toboroz
Luminal Breast Cancer Cryoablation
NCT07447414· Lucía Graña López· Forrás
Contact: Lucía Graña López, PhD
Toboroz
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· 4. fázis· Sanofi· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Még nem toboroz
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· 2. fázis· Elevara Medicines Limited· Forrás
Még nem toboroz
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592· PETHEMA Foundation· Forrás
Contact: Aitor Abuín, Dr (principal investigator)
Toboroz
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674· 3. fázis· Amgen· Forrás
Toboroz
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT06736899· Fundación EPIC· Forrás
Contact: JORGE PALAZUELOS, MD, PhD
Toboroz
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
2025-521640-38-00· 3. fázis· Praxis Precision Medicines Inc.· Forrás
Toboroz
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
NCT07246863· 2. fázis· CatalYm GmbH· Forrás
Toboroz
SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial
2024-512132-29-00· 2. fázis· Swiss Group for Clinical Cancer Research· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· 3. fázis· Gilead Sciences Inc.· Forrás
Fut, nem toboroz
Support C Post-Market Registry
NCT06678490· OrbusNeich· Forrás
Toboroz
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
NCT07153445· 2. fázis· Fundación GECP· Forrás
Fut, nem toboroz
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
NCT06315010· 2. fázis· MedSIR· Forrás
Toboroz
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
NCT06856213· 2. fázis· Grupo Español de Tratamiento de Tumores de Cabeza y Cuello· Forrás
Toboroz
Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).
NCT06736665· Spanish Society of Cardiology· Forrás
Contact: Jeremías Bayón Lorenzo, MD, PhD.
Toboroz
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615· 2. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· 2/3. fázis· Eikon Therapeutics· Forrás
Toboroz
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577· 2. fázis· AstraZeneca· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805· 2. fázis· Mediar Therapeutics· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study to evaluate the safety and efficacy of a treatment consisting of immunotherapy by subcutaneous injection of a combination of Der p 1/Der p 2/Der p 23 allergens at different doses in patients with allergic rhinitis or rhinoconjunctivitis with or without allergic asthma.
2024-518519-20-01· 2. fázis· Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.· Forrás
Fut, nem toboroz
EucaLimus Post-Market Registry
NCT06621524· OrbusNeich· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· 3. fázis· Celgene· Forrás
Toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514· 3. fázis· Summit Therapeutics· Forrás
Toboroz
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
NCT06431633· 3. fázis· Fundación GECP· Forrás
Toboroz
ANALYSIS OF EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED COLON CANCER.
2024-519825-39-00· 2. fázis· Clinica Universidad De Navarra· Forrás
Toboroz
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· 3. fázis· Cytokinetics· Forrás
Showing 50 of 103.